RE:Another "buy" rating $8.00 ( usd) 2020 Annual Meeting of Shareholders
A year in review: clinical progress and positive feedback
The 2020 Annual Meeting of Shareholders was like no meeting the company has ever held. There were about 150 people listening . . . but no one attended. In these unprecedented times, the meeting was virtual for the safety of management, the board, our shareholders and all those we hold near and dear to our hearts. But the show must go on!
The 2020 Annual Meeting of Shareholders’ corporate update presentation highlighted the excitement in the oncolytic virus space. The reason for the excitement was clear, as is the clinical and business development progress Oncolytics has made. Most importantly, we discussed very positive feedback from leading key opinion leaders in the breast cancer space, suggesting, as one KOL put it, that pelareorep is “The most exciting immune activator approach I have come across”. Dr. Matt Coffey highlighted the excitement for checkpoint inhibitors – a drug class that accounted for over $19 billion in sales in 2019 – the significant limitations of checkpoint blockade and how pelareorep could help overcome those limitations to increase the addressable patient population for these drugs.
The presentation covered our ongoing clinical programs, as well as significant interest from KOL’s that would like to begin studying pelareorep in gastrointestinal cancers. Mr. Kirk Look, Chief Financial Officer at Oncolytics, wrapped the presentation with comments on the company’s strong cash position and our anticipated milestones and newsflow.
If you haven’t had a chance to listen to the presentation in full, please check it out here.